IP Library Granted Patent US 8,895,711
Granted Patent B2
US 8,895,711 · App. 12/296,275 · Granted Nov 25, 2014

Mutated ACVR1 for diagnosis and treatment of Fibrodyplasia Ossificans Progressiva (FOP)

Inventors: Frederick S. Kaplan (Philadelphia, PA); Eileen M. Shore (Fort Washington, PA)
Assignee: The Trustees of the University of Pennsylvania
G01N33/6893C12Q2600/156G01N2800/10A01K2217/075A01K2267/0306A01K2227/105C07K14/4713A01K2207/15A01K2217/00A61K38/00C07K14/71C07K14/001C12N15/8509C12Q1/6883
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,895,711
App. No.
12/296,275
Granted
Nov 25, 2014
Kind
B2
Abstract

This invention is directed to mutated Activin A type I receptor proteins (ACVR1) and isolated nucleic acids encoding same. The invention also relates to the use of mutated ACVR1 in the diagnosis and treatment of Fibrodysplasia Ossificans Progressiva (FOP).

Claims (18)

1. A molecular beacon nucleic acid comprising a stem and a loop and a detectable label, wherein the loop consists of at least 15 contiguous bases of SEQ ID NO: 34 or of at least 15 contiguous bases of the complement of SEQ ID NO: 34, wherein position 11 of SEQ ID NO: 34 is an A.

2. A method of diagnosing Fibrodysplasia Ossificans Progressiva (FOP) in a human subject, said method comprising:

contacting a biological sample containing ACVR1 nucleic acids from said subject with the molecular beacon of claim 1 ;

detecting the presence of an ACVR1 nucleic acid that encodes histidine at the position corresponding to position 206 of SEQ ID NO: 21; and

correlating the presence of an ACVR1 nucleic acid that encodes histidine at the position corresponding to position 206 of SEQ ID NO: 21 with a diagnosis of FOP in the subject.

3. The method of claim 2 wherein the FOP is inherited FOP.

4. The method of claim 2 wherein the FOP is sporadic FOP.

5. The method of claim 2 , wherein the molecular beacon has a photoluminescent dye at on one of the 5′ or 3′ ends and a quenching agent at the opposite 3′ or 5′ end.

6. The method of claim 2 , further comprising a step wherein ACVR1 nucleic acids from the subject are amplified.

7. A kit for diagnosing FOP in a subject, said kit comprising the molecular beacon of claim 1 .

8. A method of diagnosing Fibrodysplasia Ossificans Progressiva (FOP) in a human subject, said method comprising:

amplifying by PCR ACVR1 nucleic acids in a biological sample from said subject;

contacting the amplified ACVR1 nucleic acids with the molecular beacon of claim 1 ;

detecting the presence of an ACVR1 nucleic acid that encodes histidine at the position corresponding to position 206 of SEQ ID NO: 21; and

correlating the presence of an ACVR1 nucleic acid that encodes histidine at the position corresponding to position 206 of SEQ ID NO: 21 with a diagnosis of FOP in the subject.

9. The method of claim 8 wherein the FOP is inherited FOP.

10. The method of claim 8 wherein the FOP is sporadic FOP.

11. The method of claim 8 , wherein the molecular beacon has a photoluminescent dye at on one of the 5′ or 3′ ends and a quenching agent at the opposite 3′ or 5′ end.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jan 7, 2019
From: UNIVERSITY OF PENNSYLVANIA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 048020/0874 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 2, 2008
From: KAPLAN, FREDERICK S.; SHORE, EILEEN M.
To: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Reel/Frame 021772/0319 →
Continuity (2)
Provisional Application 60792646 · Apr 18, 2006
Related Publication 20090253132A1 · Oct 8, 2009